Workflow
Rani Therapeutics signs up to $1.09 billion licensing deal with Japan's Chugai Pharma
Rani Therapeutics Rani Therapeutics (US:RANI) Reutersยท2025-10-17 11:48

Core Insights - Rani Therapeutics has entered into a licensing agreement with Chugai Pharmaceutical for an oral drug, with the potential to extend the deal to five additional drugs, which could increase the total deal value to $1.09 billion [1] Company Summary - The agreement allows Chugai Pharmaceutical to license an oral drug developed by Rani Therapeutics [1] - The potential extension of the deal to five drugs indicates a significant opportunity for Rani Therapeutics to expand its market presence and revenue [1] Financial Implications - The total deal value of $1.09 billion highlights the financial significance of the partnership for Rani Therapeutics [1]